Jennifer Cunningham, a nurse, saw that her husband's eye looked smaller. Eventually, he decided to see a doctor. He had a ...

Three equities stand out among the plethora of alternatives as possible Wall Street game-changers. Each represents a distinct ...

The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors. Read More on FHTX: Foghorn Therapeutics ...

Maher agrees, and notes as well that, in rare cases, "nose bleeding may also indicate a hematologic or bleeding disorder." ...

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that company ...

The Northwell Health Cancer Institute and its Center for Genomic Medicine announced the opening of Long Island’s first clinical Molecular Diagnostics Laboratory (MDL), a $3.2 mi ...

Swiss company ADC Therapeutics has announced a $105 million underwritten offering of common shares and pre-funded warrants. The Lausanne-based firm is advancing its proprietary ADC technology in an ...

In a joint conference event on Monday, cell therapy pioneer Carl June revealed unpublished results showing that in around 1,500 patients treated with CAR-T therapies, no cases of secondary malignancy ...

Fintel reports that on May 6, 2024, Leerink Partners upgraded their outlook for Blueprint Medicines (NasdaqGS:BPMC) from ...

The Company’s lead product candidate, azenosertib (ZN-c3), is a potentially first-in-class and best-in-class WEE1 inhibitor for advanced solid tumors and hematologic malignancies. Azenosertib is being ...